Zelia M. Correa, an expert in ocular oncology, has joined Sylvester Comprehensive Cancer Center and Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine as co-director of the ocular oncology service.
Karyn Aalami Goodman was named associate director for clinical research at Mount Sinai's The Tisch Cancer Institute. She is also professor and vice chair for research and quality in the Department of Radiation Oncology.
Lillian L. Siu will receive the European Society for Medical Oncology's TAT 2020 Honorary Award for her contributions in the development of new anticancer drugs, particularly with respect to phase I trials in head and neck malignancies.
Thomas Sellers, former director of Moffitt Cancer Center, has filed a lawsuit against his former institution, claiming defamation and tortious interference with a business relationship.
The pace of innovation in oncology has made U.S. cancer researchers prime targets for foreign state-sponsored programs aimed at diverting intellectual property.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
European Medicines Agency accepted the Marketing Authorization Application for tucatinib, in combination with trastuzumab and capecitabine, for the treatment of adult patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received at least two prior anti-HER2 treatment regimens.
European Medicines Agency validated the marketing authorization application for belantamab mafodotin for the treatment of patients with relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.
Committee for Medicinal Products for Human Use Jan. 30 adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ruxience , intended for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and Pemphigus vulgaris.
FDA and the Federal Trade Commission signed a joint statement Feb. 3 on enhanced collaboration in support of a robust marketplace for biological products, including the critical adoption of biosimilars and interchangeable products.
